Klaus Breiner, PhD, is a Managing Partner at BB Pureos Bioventures. Over the last two decades, Dr. Breiner has invested in a broad range of life science companies.
Before becoming a venture capitalist, he was a business consultant with Booz Allen & Hamilton in Zurich, and a researcher at the Swiss Federal Institute of Technology in Zurich and at the Center for Molecular Biology in Heidelberg.
Dr. Breiner holds an MA in chemistry from the University of North Carolina, Chapel Hill, and a PhD in molecular biology from the University of Heidelberg.
Dr. Breiner’s past and present board assignments include Agendia BV, AM-Pharma BV, Alpex Pharma SA, Cadence Pharmaceuticals Inc., Glycart Biotechnology AG, Orthocon Inc, and Vaximm AG.